Core Viewpoint - Doximity (DOCS) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - Doximity's rising earnings estimates and the subsequent rating upgrade suggest an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [9][10]. Earnings Estimate Revisions for Doximity - Doximity is expected to earn $1.46 per share for the fiscal year ending March 2026, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for Doximity has increased by 4.9%, reflecting analysts' positive revisions [8].

Company Performance - Doximity's stock (DOCS) decreased by 1.44% to $59.38, underperforming the S&P 500's daily gain of 0.06% [1] - Over the past month, Doximity's stock has increased by 3.92%, while the Medical sector has declined by 1.83% and the S&P 500 has risen by 5.88% [1] Earnings Forecast - Doximity is expected to release its earnings on August 7, 2025, with a forecasted EPS of $0.31, reflecting a 10.71% increase from the same quarter last year [2] - Revenue is projected to be $139.67 million, indicating a 10.26% growth compared to the corresponding quarter of the previous year [2] Full-Year Estimates - The Zacks Consensus Estimates for Doximity's full-year earnings are $1.46 per share and revenue of $625.72 million, representing year-over-year changes of +2.82% and +9.7%, respectively [3] - Recent adjustments to analyst estimates suggest evolving short-term business trends, with positive revisions indicating analyst optimism [3] Valuation Metrics - Doximity has a Forward P/E ratio of 41.3, which is higher than the industry average of 28.27 [6] - The company also has a PEG ratio of 4.48, compared to the Medical Info Systems industry's average PEG ratio of 3.23 [6] Industry Ranking - The Medical Info Systems industry, part of the Medical sector, holds a Zacks Industry Rank of 81, placing it in the top 33% of over 250 industries [7] - The Zacks Industry Rank is based on the average Zacks Rank of individual stocks within the industry, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]

Company Performance - Doximity (DOCS) closed at $61.55, with a +2.24% increase from the previous day, outperforming the S&P 500's gain of 0.14% [1] - Prior to the latest trading session, Doximity shares had gained 7.65%, contrasting with the Medical sector's loss of 1.34% and the S&P 500's gain of 3.97% [1] Earnings Expectations - The upcoming earnings report is expected to show an EPS of $0.31, reflecting a 10.71% increase year-over-year [2] - Revenue is anticipated to be $139.67 million, indicating a 10.26% rise compared to the same quarter last year [2] - For the annual period, earnings are projected at $1.46 per share and revenue at $625.72 million, representing increases of +2.82% and +9.7% respectively from the previous year [3] Analyst Estimates - Recent modifications to analyst estimates for Doximity suggest a favorable outlook on the company's business health and profitability [4] - The Zacks Rank system indicates that changes in estimates are correlated with stock price performance, with Doximity currently holding a Zacks Rank of 3 (Hold) [5][6] Valuation Metrics - Doximity is trading at a Forward P/E ratio of 41.26, which is a premium compared to the industry average of 28.13 [7] - The company has a PEG ratio of 4.48, while the Medical Info Systems industry has an average PEG ratio of 2.64 [8] Industry Context - The Medical Info Systems industry, part of the Medical sector, holds a Zacks Industry Rank of 85, placing it in the top 35% of over 250 industries [9] - Research indicates that industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [9]

Doximity's Business Overview - Doximity is a leading digital platform for doctors, boasting a network that includes over 80% of all U S physicians[6] - The platform offers networking, news, scheduling, eSignatures, collaboration, and communication tools tailored for healthcare professionals[13, 15] - Doximity aims to bring technology to medicine, drawing inspiration from enterprise tech solutions[12] Financial Performance and Metrics - Doximity achieved a net revenue retention rate of 119%[6] - The company's subscription revenue grew by 21%[6] - Doximity's adjusted EBITDA margin stands at 55%[6] - The number of customers with over $500,000 in revenue increased by 17% year-over-year[57] Market Opportunity and Solutions - Doximity addresses inefficiencies in healthcare, where 70% of U S healthcare communication is still sent via fax[11] and 75% of physicians attribute burnout to electronic health record (EHR) inefficiencies[9] - The company's marketing solutions drive the largest revenue, with health systems achieving a 17:1 ROI and pharmaceutical companies seeing over 11:1 ROI[32, 34]

Group 1 - Doximity (NYSE: DOCS) has moderate growth rates, with guidance indicating barely above double-digit growth [1] - The company presents strong investment potential, being part of a portfolio of undervalued stocks with rapid growth potential driven by quality management [1] - The marketplace emphasizes the importance of selecting attractive investments and highlights the work done in identifying the best stocks [2] Group 2 - The investment approach focuses on delivering strong gains and emphasizes deep value returns, indicating a commitment to high-quality stock picks [3] - The marketplace is experiencing rapid growth, suggesting increasing interest and engagement from members [3] - Member reviews indicate satisfaction with the actionable and insightful stock picks provided [3]

Company Performance - Doximity (DOCS) closed at $61.09, with a +1.13% change from the previous day, outperforming the S&P 500's gain of 0.52% [1] - The stock has increased by 16.31% over the past month, significantly surpassing the Medical sector's gain of 3.5% and the S&P 500's gain of 5.95% [1] Upcoming Earnings Report - Doximity is expected to report an EPS of $0.31, reflecting a 10.71% increase from the same quarter last year [2] - Revenue is forecasted at $139.67 million, indicating a 10.26% rise compared to the same quarter last year [2] Full Year Projections - For the full year, earnings are projected at $1.46 per share, with a revenue estimate of $625.72 million, showing increases of +2.82% and +9.7% respectively from the previous year [3] Analyst Estimates and Confidence - Recent changes in analyst estimates for Doximity are important as they reflect near-term business trends, with positive revisions indicating analysts' confidence in the company's performance [3][4] Zacks Rank and Performance - Doximity currently holds a Zacks Rank of 3 (Hold), with a consensus EPS projection that has increased by 0.5% in the past 30 days [5] - The Zacks Rank system has a proven track record of outperformance, with 1 stocks returning an average of +25% annually since 1988 [5] Valuation Metrics - Doximity has a Forward P/E ratio of 41.41, which is a premium compared to the industry average Forward P/E of 32.04 [6] - The company has a PEG ratio of 4.49, higher than the industry average PEG ratio of 2.75 [7] Industry Ranking - The Medical Info Systems industry, to which Doximity belongs, ranks in the top 31% of all industries, with a current Zacks Industry Rank of 74 [7]

Core Insights - Doximity (DOCS) is evolving from a physician-focused social network to a comprehensive healthcare technology platform, emphasizing enterprise offerings such as workflow tools and AI solutions as key growth drivers [1][5] Company Developments - In Q4 FY2025, Doximity reported significant traction in workflow tools, including telehealth and AI documentation, reaching over 620,000 unique prescribers, with AI usage increasing more than fivefold year-over-year [2][9] - The company is positioning its enterprise tools as a "second act," moving away from its original focus on pharmaceutical marketing [2][5] - Doximity's enterprise offerings are expected to enhance revenue predictability, with integrated multi-module launches occurring earlier in the fiscal year [3][4] Financial Performance - Doximity achieved a net revenue retention rate of 119% and a full-year growth rate of 20%, driven by its client portal that helps pharma clients track ROI and identify upsell opportunities [3][9] - The company's stock has gained 12.7% year-to-date, compared to the industry growth of 20% [8] Market Positioning - While advertising remains a core business, Doximity is shifting its focus towards clinical utility and platform value, with point-of-care tools expected to become significant revenue contributors [4][5] - The transition to enterprise solutions involves longer sales cycles and more complex implementations, but Doximity is committed to retraining its teams to support this shift [4][9] Valuation Metrics - Doximity's forward 12-month price-to-sales (P/S) ratio is 17.8X, significantly higher than the industry average of 6X and its five-year median of 13.5X [11] - The Zacks Consensus Estimate for Doximity's fiscal 2026 earnings per share indicates a 2.8% improvement from fiscal 2025 [13]

Core Insights - Doximity (DOCS) is leveraging artificial intelligence to drive growth following a strong fiscal 2025, introducing tools like Doximity GPT to enhance clinician workflows and achieve a 20% revenue increase [1][10] - The company anticipates growth at approximately twice the market rate, positioning itself favorably in the high-margin pharma marketing sector [1][10] Group 1: AI Tools and Revenue Impact - Doximity GPT and other AI tools have seen strong adoption, but management has not quantified their revenue impact, indicating that these initiatives are still in the early stages of development [2][10] - The reliance on pharma marketing dollars remains significant, with potential for AI tools to enhance user engagement and open new monetization avenues in premium subscriptions and value-added services [3][4] Group 2: Long-term Growth Potential - While immediate revenue boosts from AI are unlikely, the technology is expected to support a more sustainable and diversified growth trajectory over time [4][5] - With over 80% of U.S. physicians on the platform, Doximity is well-positioned to capitalize on operational execution and increased adoption of AI tools [5] Group 3: Competitive Landscape - Other companies, such as Certara and GE HealthCare, are also developing AI tools to remain competitive, with Certara reporting an 18% year-over-year increase in software revenues due to AI uptake [7][8] - GE HealthCare has invested significantly in AI across its product offerings, showcasing new AI-enabled diagnostics and planning to launch nearly 200 AI/ML-enabled devices in the next three years [8] Group 4: Financial Performance and Valuation - Doximity's shares have increased by 6.9% year-to-date, underperforming the industry average growth of 28% [9] - The forward 12-month price-to-sales ratio for Doximity is 16.9X, significantly higher than the industry average of 6X and its five-year median of 13.5X, indicating a premium valuation [12]

Core Insights - Doximity (DOCS) and iRhythm Technologies (IRTC) are prominent players in AI-powered healthcare, with Doximity focusing on clinician engagement and workflow, while iRhythm specializes in AI-driven cardiac monitoring [2][4] - Doximity reported fiscal 2025 revenues of $570.4 million, a 20% increase year-over-year, and a 48% rise in operating cash flow [2] - iRhythm Technologies achieved full-year 2024 revenues of $591.8 million, reflecting a 20.1% year-over-year growth [3] Company Overview - Doximity serves over 80% of U.S. physicians with a platform that includes telehealth and workflow tools [5] - iRhythm Technologies focuses on AI-driven cardiac monitoring through its Zio platform, which provides clinically validated diagnostics [5] Financial Performance - Doximity's fourth quarter of fiscal 2025 saw revenues of $138.3 million and net income of $62.5 million, with a 56% increase in free cash flow [7] - iRhythm's first-quarter 2025 revenues reached $158.7 million, a 20.3% year-over-year increase, despite a net loss of $30.7 million [10] Stock Performance - Year-to-date, Doximity's share price increased by 6.9%, while iRhythm's surged by 61.4% [6][9] - Doximity's stock performance is impacted by risks related to drug-pricing reforms and changes in pharmaceutical advertising budgets [6] AI Integration - Doximity has integrated AI into clinical workflows, notably with Doximity GPT, which automates documentation [11] - iRhythm employs AI for diagnostics through its Zio platform, supported by the ZEUS AI system for interpreting cardiac data [13] Growth Outlook - Doximity anticipates fiscal 2026 revenues between $619 million and $631 million, with adjusted EBITDA of $333-$345 million [14] - iRhythm raised its revenue outlook for the full year to $690-$700 million, with EBITDA margins projected at 7.5-8.5% [14] Investment Appeal - Doximity is viewed as a stable investment with profitability and a large user base, appealing to risk-averse investors [19] - iRhythm presents a higher-risk, higher-reward opportunity driven by innovative diagnostics and expanding clinical applications [19]

Doximity (NYSE: DOCS ) provides a digital platform for U.S. medical professionals with 2 million members, covering 80% of U.S. physicians. Its platform enables healthcare professionals to access the latest medical information, recruit staff, and streamline clinical workflows. I view Doximity as the "LinkedIn" for healthcare professionals, and I am initiatingAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such posi ...